Amicus Therapeutics, Inc.
FOLDDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178879
Amicus Therapeutics, Inc. was delisted in 2026; its insiders filed their last Form 4 on Apr 27, 2026; 298 institutions reported holding it in 13F filings for Q1 2026, worth $4.81B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 298
- Q1 2026, −26 vs. previous quarter
- 13F value
- $4.81B
- Reported value at the end of Q1 2026
- Superinvestors holding
- 1
- At the end of Q1 2026
Superinvestors holding FOLD, Q1 2026
1 superinvestor reports holding Amicus Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
1.1%
Amicus Therapeutics, Inc.'s share of the portfolio
- Shares
- 5,753,186
- Value
- $83.2M
Latest insider trades
Open-market purchases and sales by Amicus Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Campbell Bradley LPresident and CEO | SSale | −22.5K | $14.35 | −$322.9K | −2.2%998.7K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Campbell Bradley LPresident and CEO | SSale | −75.0K | $14.31 | −$1.07M | −6.8%1.02M after | 10b5-1 |
| Dec 23, 2025 (view filing) | Dec 19 | 4 days | Clark David MichaelChief People Officer | SSale | −25.6K | $14.17 | −$363.3K | −9.5%245.7K after | 10b5-1 |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Campbell Bradley LPresident and CEO | SSale | −77.9K | $10.86 | −$846.3K | −6.5%1.13M after | 10b5-1 |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Clark David MichaelChief People Officer | SSale | −25.6K | $11.00 | −$282.1K | −8.6%271.3K after | 10b5-1 |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Campbell Bradley LPresident and CEO | SSale | −14.6K | $10.01 | −$146.0K | −1.3%1.14M after | 10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24 | 2 days | Castelli JeffChief Development Officer | SSale | −76.2K | $10.16 | −$773.8K | −14.8%439.3K after | 10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24 | 2 days | Clark David MichaelChief People Officer | SSale | −25.6K | $10.10 | −$259.0K | −7.9%297.0K after | 10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24 | 2 days | Campbell Bradley LPresident and CEO | SSale | −14.6K | $10.04 | −$146.5K | −1.3%1.14M after | 10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24-26 | 2 days | Rosenberg EllenChief Legal Officer | SSale | −95.6K | $10.02 | −$958.4K | −15.8%507.7K after | 3 lots10b5-1 |
Top 10 13F holders, Q1 2026
The largest institutional positions in Amicus Therapeutics, Inc. at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 33,879,048 | $489.9M | 0.01% | +1,354,667+4.2% | Added |
| UBS Group AG | 15,957,913 | $230.8M | 0.04% | +10,064,625+170.8% | Added |
| Vanguard Capital Management LLC | 14,023,557 | $202.8M | 0.01% | +14,023,557 | New |
| Pentwater Capital Management LP | 14,000,000 | $202.4M | 1.44% | +2,500,000+21.7% | Added |
| Vanguard Portfolio Management LLC | 13,974,932 | $202.1M | 0.01% | +13,974,932 | New |
| State Street Corp | 12,893,897 | $186.4M | 0.01% | −1,939,417−13.1% | Reduced |
| Glazer Capital, LLC | 12,722,749 | $184.0M | 3.91% | +11,118,961+693.3% | Added |
| FIL Ltd | 12,560,028 | $181.6M | 0.14% | +11,603,028+1,212.4% | Added |
| Goldman Sachs Group Inc | 11,556,008 | $167.1M | 0.02% | +5,413,052+88.1% | Added |
| Qube Research & Technologies Ltd | 8,809,340 | $127.4M | 0.18% | +4,374,661+98.6% | Added |